Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Gains from Investment Securities (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Gains from Investment Securities for 14 consecutive years, with $31000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Gains from Investment Securities changed N/A year-over-year to $31000.0, compared with a TTM value of $31000.0 through Sep 2025, up 542.86%, and an annual FY2023 reading of -$7000.0, changed 0.0% over the prior year.
  • Gains from Investment Securities was $31000.0 for Q2 2025 at Alaunos Therapeutics, up from $5000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $307000.0 in Q4 2021 and bottomed at -$559000.0 in Q1 2021.
  • Average Gains from Investment Securities over 4 years is -$16727.3, with a median of -$2000.0 recorded in 2023.
  • Peak annual rise in Gains from Investment Securities hit 30800.0% in 2021, while the deepest fall reached 850.0% in 2021.
  • Year by year, Gains from Investment Securities stood at $307000.0 in 2021, then plummeted by 102.28% to -$7000.0 in 2022, then skyrocketed by 171.43% to $5000.0 in 2023, then soared by 520.0% to $31000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for TCRT at $31000.0 in Q2 2025, $5000.0 in Q4 2023, and -$2000.0 in Q3 2023.